Royce & Associates LP Has $9.99 Million Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Royce & Associates LP grew its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 33.6% in the fourth quarter, HoldingsChannel reports. The fund owned 458,335 shares of the company’s stock after acquiring an additional 115,176 shares during the period. Royce & Associates LP’s holdings in Stevanato Group were worth $9,987,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Van Berkom & Associates Inc. bought a new stake in shares of Stevanato Group in the fourth quarter worth $39,000. PNC Financial Services Group Inc. increased its stake in Stevanato Group by 1,457.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock valued at $123,000 after buying an additional 5,291 shares during the last quarter. US Bancorp DE lifted its position in Stevanato Group by 17.9% during the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after buying an additional 1,295 shares in the last quarter. Marco Investment Management LLC bought a new position in shares of Stevanato Group in the 4th quarter valued at about $203,000. Finally, Hardy Reed LLC increased its position in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after acquiring an additional 840 shares during the last quarter.

Wall Street Analysts Forecast Growth

STVN has been the subject of several recent research reports. Wolfe Research started coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price target for the company. UBS Group decreased their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America lifted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Stevanato Group presently has an average rating of “Moderate Buy” and an average target price of €27.75 ($30.16).

Stevanato Group Stock Performance

NYSE:STVN opened at €20.71 ($22.51) on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.00) and a fifty-two week high of €33.49 ($36.40). The company has a market cap of $6.27 billion, a price-to-earnings ratio of 44.06, a PEG ratio of 7.18 and a beta of 0.60. The stock has a fifty day moving average price of €21.16 and a 200-day moving average price of €20.58.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The business had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, equities analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.